•  
  •  
    • What is Euflexxa?
    • Is Euflexxa right for me?
    • Why choose Euflexxa?
    • Euflexxa FAQs
  •  
    • About OA of the knee
    • Signs, Symptoms and Causes
    • Diagnosis
    • Treatment
  •  
    • Euflexxa Experience
    • Hear from patients like you
    • Learn more from OA experts
    • Ask a Doctor
  •  
A A A Text Size   e-mail Email a Friend   print Print this Page

Learn more from OA experts

  • What is Osteoarthritis of the Knee?
  • What are the Risk Factors for Osteoarthritis?
  • What Roles do Diet and Exercise Play in Osteoarthritis Treatment?
  • Is Osteoarthritis Preventable?
  • What are Some Over-the-Counter Treatment Options for Osteoarthritis?
  • Do I need a referral to see a Rheumatologist?
  • What is the difference between this type of injection and steroid injection?
  • Is viscosupplementation treatment used alone or in conjuction with other treatments?
  • What outcome does a doctor hope to achieve with the use of viscosupplementation treatments?
  • How can someone tell if they have Osteoarthritis? How is it Diagnosed?

spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer

Find us on Facebook

EUFLEXXA (1% sodium hyaluronate) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (eg, acetaminophen).

Important Safety Information
EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA. The safety and effectiveness of repeated treatment cycles weeks with EUFLEXXA have not been established.

In a randomized, double-blind, multicenter clinical trial (N=160 EUFLEXXA), the only adverse event reported with EUFLEXXA at an incidence greater than 5% was arthralgia (8.7%).

Full Prescribing Information.

Important Information for Patients.

The information on this website is provided for educational purposes only. While there may be information on this web site related to certain medical conditions and their treatment, should a medical condition exist, promptly see your own physician or health provider as the information on this website is not intended to take the place of advice from a physician or healthcare professional. Ferring does not offer personalised medical diagnosis or patient-specific treatment advice. The statements made by doctors on this website represent their own individual experience and opinion and is not intended to be medical advice. Indeed, only your doctor or other health care professional, as a learned intermediary, can determine if a product described in this web site is appropriate for you.

PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.

This website is intended only for US residents.

©2005-2010 Ferring Pharmaceuticals Inc. All rights reserved. | About Ferring Privacy Policy | Legal Disclaimer